Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Linavonkibart by Scholar Rock for Colorectal Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Linavonkibart by Scholar Rock for Prostate Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
Linavonkibart by Scholar Rock for Nasopharyngeal Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase...
Linavonkibart by Scholar Rock for Uterine Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Linavonkibart by Scholar Rock for Liver Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Scholar Rock Holding's Linavonkibart?
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Ovarian Cancer;Uterine Cancer....
Risk adjusted net present value: What is the current valuation of Scholar Rock Holding's Linavonkibart?
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Oropharyngeal Cancer. According...